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 Retinitis pigmentosa (RP) is a heterogeneous group of
retinal dystrophies, characterized by photoreceptor cell degen-
eration leading to night blindness and visual field loss. Clini-
cal manifestations include pigment deposition in the retina and
attenuation of retinal blood vessels, with later de-pigmenta-
tion or atrophy of the retinal pigment epithelium. Electroret-
inogram (ERG) changes are present with abnormalities of both
rod and cone ERGs but with the rod ERGs more affected than
the cone ERGs (rod-cone dystrophy). In advanced RP both
rod and cone ERG responses are undetectable [1]. With an
incidence of around 1 in 3500, RP can be inherited as an X-
linked, autosomal dominant or autosomal recessive condition.
Autosomal dominant RP (adRP) can be caused by mutations
in at least 13 genes (RetNet; Retina Disease Database), one of
which is the gene PRPF31 localized on chromosome 19q13.4
(RP11) [2]. The gene is comprised of 14 exons spaning ap-
proximately 16 kb of genomic DNA and encodes a ubiqui-
tously expressed 61K splicing factor protein PRPF31, also
referred to as splicing factor 61K.
In order to determine the mutation spectrum of PRPF31
in adRP we and others have screened the coding exons and
their flanking splice sites in families linked to this locus and
in large patient cohorts [2]. Over 30 different mutations have
been reported that include missense, deletion, insertion and
splice site alterations. It has been speculated that
haploinsufficiency may be the cause of disease [2] but to date
there has been no evidence to prove that this mechanism rather
than aberrant function of mutated protein is responsible for
disease. In this study we report the largest deletion identified
in the PRPF31 gene thus providing evidence that
haploinsufficiency is the cause of disease in adRP patients with
mutations in the PRPF31 gene.
METHODS
Patients:  We previously mapped the adRP locus on chromo-
some 19q13.4 and identified several adRP families linked to
this locus [3,4]. After subsequent cloning of the PRPF31 gene
mutations were identified in all but one family referred to as
ADRP2. Patients from this family were the subjects of this
study. The study protocol was approved by the hospital ethics
committee and was in accordance with the tenets of the Dec-
laration of Helsinki (June 1964); informed consent was ob-
tained from all members after explanation of the nature and
possible consequences of the study. Although DNA of more
than 17 members (disease status known) of this three-genera-
tion British family is available, only seven members were avail-
able for ophthalmic reexamination. The youngest patient ex-
amined was 11 years of age and the oldest 47. A detailed his-
tory was taken, focussing on the typical signs of RP and their
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onset. All patients had electrophysiological testing performed
with gold foil recording electrodes and Ganzfeld stimulation
according to the ISCEV Standard responses, including the
higher intensity flash “suggested” in the recent version of the
ISCEV Standard for ERG [5].
Mutation analysis and genotyping:  The 14 exons of
PRPF31 were screened for mutations by systematic sequenc-
ing of PCR products as described previously [2].
To assess the possibility of a large intragenic deletion,
nine PRPF31 intragenic single nucleotide polymorphisms
(SNPs) were typed in ADRP2 (420+81T >C, 420+82G >C,
528-31C >T, 564G >A, 735C >T, 855+40G >A, 946-70T >C,
1148-9T >C, and 1468C >T). In addition several SNPs and
microsatellite markers flanking PRPF31 were also analyzed
in the family. The location of the analyzed markers, sequence
of each set of primers and conditions are described in Table 1.
PCR products harboring SNPs were analyzed by direct se-
quencing using an ABI 3100 (Applied Biosystems, Foster city,
CA) while PCR products of microsatellite markers were sepa-
rated by non-denaturing PAGE (Protogel; National Diagnos-
tics USA, Atlanta, GA) and visualized under UV illumination
after being stained with ethidium bromide.
RESULTS
Patient clinical data:  All examined members of this three-
generation British family were affected thus displaying a high
degree of disease penetrance. Four out of the seven members
examined are shown in the pedigree (III.3, III.9, IV.1, and IV.2
in Figure 1A); younger affected members for whom genotype
data are not available are not shown. The onset of night blind-
ness was reported between the age of 3 and 16 years. Visual
field loss was first noticed between the age of 6 and 30 years.
Photoaversion and visual loss if present-was noticed in most
cases about 15 years after the onset of visual field loss. By the
age of 40 most patients had severely reduced visual fields with
a central island of 2-5°. However, visual acuity (VA) was rela-
tively well preserved (6/9-6/18) with one exception (III.9)
whose VA was counting fingers. The more advanced cases all
had a small posterior subcapsular opacity or had been oper-
ated for cataract.
Fundus examination revealed advanced disease with
heavy bone spicule pigmentation and severe atrophy by the
age of 30 to 40 years. The youngest patient examined, despite
being asymptomatic at that stage showed at age 11 some mild
atrophy in the midperiphery associated with some inferior bone
spicule pigmentation. The most severely affected patient (III.9)
had severe maculopathy with a bull’s eye appearance in addi-
tion to the peripheral retinopathy.
The majority of patients had undetectable full-field ERGs
under all standard stimulus and recording conditions. Only
one patient, aged 19 years showed some residual ERG activ-
ity but was severely abnormal.
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TABLE 1. MARKERS AND PRIMERS USED FOR DELETION ANALYSIS
Marker/SNPs   Location of marker/SNP   Sense primer (5'-3')   Antisense primer (5'-3')   Tm
-----------   ----------------------   --------------------   ------------------------   --
JST060265     Proximal to OSCAR        TGGGGTAGAAAGAGTATG     TCTATTTTCTCCAAAGACGG       56
JST060264
JST114222     5' UTR of OSCAR          GAAAGGGGTGACTCACAGAG   TTCCACAGTGCCATAGGGCT       60
(GATA)n       about 1.5 kb 5' of       TTTGCACCTATTATGTGCCA   TCACAGCAAGGGCCTGGCAC       58
              NDUFA3 start ATG
420+81T>C
420+82G>C     PRPF31 IVS5              GAGTCTCCTTCCATCTCACC   CAGAGCAGACCACTGAGCC        59
528-31C>T     PRPF31 IVS6              GGAGATCCAGGAGGCTGG     GGTCACAGTGTCAGCAGACC       61
564G>A
735C>T        PRPF31 exon8             CTCTCTGCTTTCTTCTGACC   TGAGTGCTACCGTCAGCT         60
855+40G>A     PRPF31 IVS8
946-70T>C     PRPF31 IVS9              TAAGGCACGTGGATACTCG    CATCTTGCGGTACCTGGG         61
1148-9T>C     PRPF31 IVS11             CTGGTCGCTGAACTGCAG     CCTTGCCAAGGTCTCAGG         64
1468C>T       PRPF31 exon 14           CTCACCTAACCCATCATCC    GCTCTGATTCTTCTAGTTGCC      55
(TGTT)n       about 1.4 kb 3'          GGATGATCCTGGCTCATG     GAGAATCACTTCAACCTGG        57
              of PRPF31 STOP
(CA)n         0.5 kb 5' of CNOT3       CCCCCAATCTTTCTTCTCCT   AGCTGATGACTGGGATGGAG       59
              start ATG
Markers, listed in descending order from centromere, and primers used for deletion analysis. Sequence information is based on NCBI Homo
sapiens chromosome 19 genomic sequence NT_011109. The nucleotide positions of single nucleotide polymorphysm (SNPs) within PRPF31
gene are based on the start codon in the PRPF31 gene (NM_015629).
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All the affected members of this family that were exam-
ined therefore showed the typical features of retinitis
pigmentosa. The ocular phenotype was severe. General his-
tory revealed some chronic asthma or chronic bronchitis in
two of the patients (IV.2 and younger sister). One patient (IV.1)
had some facial dysmorphia with telecanthus. However, this
was not seen in other patients and there was no clear evidence
of any obvious systemic association linked with the gene de-
fect.
Mutation analysis:  Initial screening of PRPF31 in the
ADRP2 family did not reveal any obvious mutation. How-
ever, close scrutiny of the data revealed that all affected indi-
viduals are “homozygous” for several SNPs within PRPF31.
Moreover, the homozygous alleles differed among the affected
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Figure 1. The ADRP2 pedigree with a deletion in PRPF31.  Subjects were genotyped for 15 markers within and surrounding the PRPF31 gene
and haplotypes assembled. A: Filled symbols denote affecteds, open symbols unaffecteds and grey symbols asymptomatic disease haplotype
carriers. The extent of the deletion is indicated as a solid bar within the boxed affected haplotype. N denotes untyped markers or where markers
failed to amplify. B: The schematic diagram showing the location of markers and the genes involved in the deletion. Distances between
markers are not drawn to scale. For clarity genomic organization of only PRPF31 is shown to indicate positions of single nucleotide
polymorphysms. The transcriptional direction for each gene is shown by a horizontal arrow.
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subjects suggesting that affected individuals were in fact
monoallelic at these loci. An intragenic deletion was suspected
for this apparent “homozygosity” rather than non-paternity as
several microsatellite markers within the 19q13.4 region
showed perfect segregation within the family [4]. In order to
estimate the size of the deletion, SNPs and microsatellite mark-
ers spanning and flanking PRPF31 were analyzed in the en-
tire ADRP2 family. This showed that a GATA repeat marker
located 1.5 kb upstream of the NDUFA3 gene and majority of
PRPF31 intragenic SNP markers except the ones within exon
14 were monoallelic in all affected family members (Figure
1). Close analysis of the relevant genomic sequence suggested
a deletion of approximately 30 kb that included the putative
promoter region of a novel gene OSCAR, the entire genomic
content of genes NDUFA3, TFPT and most of the PRPF31
gene except for its terminal exon (exon 14).
DISCUSSION
 The deletion of several genes adjacent to PRPF31 in this fam-
ily raised the possibility of a contiguous gene syndrome; how-
ever examination of the family members showed no obvious
indication for any other disorder besides RP.
NDUFA3 is a subunit of the NADH: ubiquinone oxi-
doreductase (complex I), the first enzyme complex in the elec-
tron transport chain of mitochondria [6]. Complex 1 is a
multimeric assembly of 7 mitochondrial-encoded subunits (ND
subunits) and at least 36 nuclear-encoded subunits. Mutations
in several nuclear genes that encode subunits of complex 1
have been associated with isolated complex I deficiency with
an autosomal recessive pattern of inheritance. The clinical
symptoms of complex I deficiency range from lethal neonatal
forms to neurodegenerative disorders in adult life, including
Leber hereditary optic neuropathy (LHON) and Parkinson dis-
ease. The fact that members of ADRP2 family do not show
symptoms of complex I deficiency may be attributed to the
fact that one copy of NDUFA3 gene is sufficient for electron
transport within complex 1. The second gene involved in the
deletion, TFPT has a promoter responsive to hematopoietic
transcriptional factors important for the early stages of B cell
differentiation and is involved in leukemia [7,8]. Therefore
TFPT may have a role in the development and/or progression
of leukemogenesis. Only the promoter is deleted in the third
gene involved in the deletion, OSCAR, which nevertheless is
likely to affect the expression of this gene. The osteoclast-
associated receptor (OSCAR) plays a critical role in osteo-
clast differentiation and is important for the maintenance of
bone homeostasis [9]. A recent study identified a promoter
variant in OSCAR that might be one of the genetic determi-
nants of Bone Mass Density (BMD) in post-menopausal
women [10]. BMD is the major factor for determining bone
strength and osteoporotic fracture risk and is determined by
both environmental and multiple genetic factors. It is possible
that females of ADRP2 with the deletion could be prone to
osteoporotic fractures with age. This however was not evi-
dent as the oldest female examined in the family was 47 years
of age. The lack of an apparent extra ocular phenotype in the
ADRP2 family suggests that one functional copy of NDUFA3,
TFPT and OSCAR is sufficient for normality. Although, a subtle
extra ocular phenotype may have been missed that could be
revealed in a more thorough clinical assessment.
The precise mechanism behind the potential deletion could
not be determined. Attempts made at amplifying across the
deletion were hindered by mis-priming of primers. However,
it is noteworthy that the PRPF31 gene has a high density of
Alu repeats. The presence of SINE/Alu repeats at both 5' and
3' ends of the deleted region suggests that an Alu-mediated
homologous recombination is responsible for this deletion. In
humans Alu sequences have repeatedly been found to be asso-
ciated with genomic deletions, such as those identified in FAA
and BRCA1 genes that cause Fanconi Anemia and breast/ova-
rian cancer, respectively [11-14].
In conclusion we have provided strong evidence for the
presence of a large deletion mutation in PRPF31 that effec-
tively results in the loss of one copy of the gene, and provide
further evidence that haploinsufficiency rather than aberrant
function of mutated proteins may be the cause of disease in
adRP patients with mutations in the PRPF31 gene.
ACKNOWLEDGEMENTS
 The authors wish to thank all of the participants in this study.
This work was supported in part by MRC grants G0000011
and G9301094, The Foundation Fighting Blindness, USA, The
British Retinitis Pigmentosa Society, Fight For Sight and the
Special Trusties of Moorfields Eye Hospital.
REFERENCES
 1. Heckenlively JR, Daiger SP. Hereditary retinal and choroidal de-
generations. In: Rimoin DL, Connor JM, Pyeritz RE, editors.
Emery and Rimoin’s principles and practice of medical genet-
ics. Vol 1. 4th ed. New York: Churchill Livingston; 2002. p.
2255-576.
2. Vithana EN, Abu-Safieh L, Allen MJ, Carey A, Papaioannou M,
Chakarova C, Al-Maghtheh M, Ebenezer ND, Willis C, Moore
AT, Bird AC, Hunt DM, Bhattacharya SS. A human homolog of
yeast pre-mRNA splicing gene, PRP31, underlies autosomal
dominant retinitis pigmentosa on chromosome 19q13.4 (RP11).
Mol Cell 2001; 8:375-81.
3. al-Maghtheh M, Inglehearn CF, Keen TJ, Evans K, Moore AT, Jay
M, Bird AC, Bhattacharya SS. Identification of a sixth locus for
autosomal dominant retinitis pigmentosa on chromosome 19.
Hum Mol Genet 1994; 3:351-4.
4. Al-Maghtheh M, Vithana E, Tarttelin E, Jay M, Evans K, Moore T,
Bhattacharya S, Inglehearn CF. Evidence for a major retinitis
pigmentosa locus on 19q13.4 (RP11) and association with a
unique bimodal expressivity phenotype. Am J Hum Genet 1996;
59:864-71.
5. Marmor MF, Holder GE, Seeliger MW, Yamamoto S, International
Society for Clinical Electrophysiology of Vision. Standard for
clinical electroretinography (2004 update). Doc Ophthalmol
2004; 108:107-14.
6. Loeffen JL, Triepels RH, van den Heuvel LP, Schuelke M, Buskens
CA, Smeets RJ, Trijbels JM, Smeitink JA. cDNA of eight nuclear
encoded subunits of NADH:ubiquinone oxidoreductase: human
complex I cDNA characterization completed. Biochem Biophys
Res Commun 1998; 253:415-22.
7. Brambillasca F, Mosna G, Colombo M, Rivolta A, Caslini C,
Minuzzo M, Giudici G, Mizzi L, Biondi A, Privitera E. Identifi-
©2006 Molecular VisionMolecular Vision 2006; 12:384-8 <http://www.molvis.org/molvis/v12/a44/>
387
cation of a novel molecular partner of the E2A gene in child-
hood leukemia. Leukemia 1999; 13:369-75.
8. Brambillasca F, Mosna G, Ballabio E, Biondi A, Boulukos KE,
Privitera E. Promoter analysis of TFPT (FB1), a molecular part-
ner of TCF3 (E2A) in childhood acute lymphoblastic leukemia.
Biochem Biophys Res Commun 2001; 288:1250-7.
9. Ishikawa S, Arase N, Suenaga T, Saita Y, Noda M, Kuriyama T,
Arase H, Saito T. Involvement of FcRgamma in signal trans-
duction of osteoclast-associated receptor (OSCAR). Int Immunol
2004; 16:1019-25.
10. Kim GS, Koh JM, Chang JS, Park BL, Kim LH, Park EK, Kim
SY, Shin HD. Association of the OSCAR promoter polymor-
phism with BMD in postmenopausal women. J Bone Miner Res
2005; 20:1342-8.
11. Petrij-Bosch A, Peelen T, van Vliet M, van Eijk R, Olmer R,
Drusedau M, Hogervorst FB, Hageman S, Arts PJ, Ligtenberg
MJ, Meijers-Heijboer H, Klijn JG, Vasen HF, Cornelisse CJ,
van’t Veer LJ, Bakker E, van Ommen GJ, Devilee P. BRCA1
genomic deletions are major founder mutations in Dutch breast
cancer patients. Nat Genet 1997; 17:341-5. Erratum in: Nat Genet
1997; 17:503.
12. Puget N, Sinilnikova OM, Stoppa-Lyonnet D, Audoynaud C,
Pages S, Lynch HT, Goldgar D, Lenoir GM, Mazoyer S. An
Alu-mediated 6-kb duplication in the BRCA1 gene: a new
founder mutation? Am J Hum Genet 1999; 64:300-2.
13. Montagna M, Santacatterina M, Torri A, Menin C, Zullato D,
Chieco-Bianchi L, D’Andrea E. Identification of a 3 kb Alu-
mediated BRCA1 gene rearrangement in two breast/ovarian
cancer families. Oncogene 1999; 18:4160-5.
14. Levran O, Doggett NA, Auerbach AD. Identification of Alu-me-
diated deletions in the Fanconi anemia gene FAA. Hum Mutat
1998; 12:145-52.
©2006 Molecular VisionMolecular Vision 2006; 12:384-8 <http://www.molvis.org/molvis/v12/a44/>
388
The print version of this article was created on 18 Apr 2006. This reflects all typographical corrections and errata to the article through that
date. Details of any changes may be found in the online version of the article. α
